ArticleFrontiers in cardiovascular medicine2025
Antithrombotic management in an elderly CABG patient with nephrotic syndrome: a case report.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adverse event profiles of fenofibrate and gemfibrozil: a retrospective comparative study and literature synthesis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Thromboembolism in the left main coronary artery of a patient with membranous nephropathy: a case report.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery bypass grafting (CABG) is a common treatment for coronary artery disease (CAD), but it poses significant perioperative risks, including thrombosis and bleeding, especially in elderly patients with comorbidities such as nephrotic syndrome and pulmonary infection. Thromboelastography (TEG) has emerged as a valuable tool for guiding dual antiplatelet therapy (DAPT) and optimizing drug treatment strategies in these complex cases. A case presentation of a 65-year-old male patient with nephrotic syndrome and pulmonary infection undergoing CABG surgery was reported. The patient's management included TEG-guided DAPT, routine monitoring of coagulation parameters, and adjustments based on clinical findings and laboratory results. TEG effectively guided DAPT and anticoagulant therapy, ensuring appropriate coagulation status and minimizing bleeding risks. The patient's postoperative management included dual antiplatelet therapy with aspirin and clopidogrel, adjusted based on TEG results. Additional interventions included the use of proton pump inhibitors to prevent gastrointestinal bleeding and tailored antibiotic therapy for pulmonary infection. The patient's clinical outcomes improved, with stable coagulation parameters and controlled infection. Clinical pharmacists play a critical role in optimizing medication regimens and ensuring patient safety through multidisciplinary collaboration. Future studies should further explore the integration of TEG and other advanced tools in personalized pharmaceutical care for complex post-CABG cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.